Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-02-24 Interim / Quarterly Rep…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 104 pages 950.4KB
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the United States SEC by Mesoblast Limited, a foreign private issuer. It covers the three and six months ended December 31, 2021, and includes unaudited financial statements, management discussion and analysis, risk factors, and other exhibits. The presence of detailed financial statements for a period shorter than a full fiscal year (quarterly and half-year data) and management discussion indicates this is an interim or quarterly report. Form 6-K is typically used by foreign private issuers to report interim financial information and other material information. The document is substantive and contains actual financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-02-24 English
Second Quarter Results Presentation 42 pages 2.8MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation including operational highlights, financial results for the quarter ended December 31, 2021, and extensive clinical and commercial information about Mesoblast's products and pipeline. It contains financial data such as revenues, cash on hand, P&L figures, and discusses clinical trial phases and outcomes. The presence of quarterly financial results and operational highlights indicates this is a quarterly or interim report rather than a full annual report or a simple announcement. The document is about 15,000 characters long, which is consistent with a substantive report rather than a brief announcement. There is no indication that this is a transcript, proxy, or regulatory filing. Therefore, the document fits best as an Interim / Quarterly Report (IR).
2022-02-24 English
MSB Q2 Financial Results and Operational Highlights 12 pages 591.0KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed operational and financial update for the period ended December 31, 2021, including financial results, refinancing activities, cash usage, revenues, and extensive operational highlights related to clinical trials, regulatory interactions with the FDA, and product development. It also includes a board update about director retirement. The document contains substantive financial data and detailed business activities, not just an announcement or summary. It is not a short announcement or a certification letter. The presence of detailed financial results and operational highlights for a specific fiscal period indicates this is a comprehensive interim or quarterly report rather than a full annual report or earnings release. Therefore, the document fits best as an Interim / Quarterly Report (IR).
2022-02-24 English
Final Director's Interest Notice 2 pages 184.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including options and ordinary shares, and notes the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director. The document length is short (2318 characters) and contains specific information about director share interests, consistent with insider trading or director dealings disclosures. Therefore, it fits the category of Director's Dealing (DIRS).
2022-02-24 English
Mesoblast Q2 Financial Results Webcast 1 page 111.9
Regulatory Filings Classification · 95% confidence The document is a short announcement about an upcoming webcast to discuss operational highlights and financial results for the second quarter ended December 31, 2021. It provides details on the webcast timing, access link, and company background. There are no actual financial statements or detailed financial data included in the text. The document length is only 2886 characters, which is quite short and consistent with an announcement rather than a full report. The text does not contain a full quarterly report or earnings release with key financial highlights, but rather an invitation to a webcast where such information will be discussed. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about an event related to financial results, not the results themselves or a transcript.
2022-02-23 English
6-K
Regulatory Filings
2022-02-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.